Microscopic detection of Mycobacterium tuberculosis in direct or processed sputum smears

Magalhães, José Luiz de Oliveira; Lima, Jaime; Araújo, Ana Albertina de; Coutinho, Ilyana Oliveira; Leal, Nilma Cintra; Almeida, Alzira Maria Paiva de

doi:10.1590/0037-8682-0238-2017

Cited by 6 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The TB treatment response measurements in endemic settings largely depend on detecting acidfast bacilli from sputum samples by smear microscopy (Mitnick et al, 2016). However, the smear microscopy detection threshold is at least 10 3 M. tuberculosis colony-forming-units in 1 mL (CFU/mL) of sputum sample (Magalhães et al, 2018). Many patients with TB/HIV coinfection have paucibacillary disease and may not produce quality sputa to detect acid-fastbacilli by smear microscopy (Das et al, 2019;Park et al, 2019).…”

Section: Phenotypic Methodsmentioning

confidence: 99%

Application of molecular methods in optimizing clinical management of patients with pulmonary multidrug resistant tuberculosis in Tanzania

Mbelele

View full text Add to dashboard Cite

Rifampicin or multidrug-resistant tuberculosis (RR/MDR-TB) accounts for considerable morbidity and mortality. Differences among Mycobacterium tuberculosis complex (MTBC) species may predict drug-resistance or treatment success. This thesis aimed at identifying MTBC at species level, their drug-resistance patterns, and mycobactericidal effect of different regimens in patients treated for RR/MDR-TB and drug-susceptible (DS-TB). This was a cross sectional study nested in a longitudinal design that followed patients on RR/MDR-TB and DS TB treatment for 4 months. While RR/MDR-TB patients received bedaquiline with or without an injectable-aminoglycoside based regimen, DS-TB patients received a fixed-dose combination comprised of rifampicin-isoniazid-pyrazinamid-ethambutol (RHZE). The genotype MTBC assay was used to identify MTBC species. WGS-based drug resistant mutations predicted the minimum-inhibitory-concentration (MIC) of antibiotics measured in the MycoTB-Sensitire™ assay. An isolate was categorised as resistant and susceptible if it had a MIC above and at or below the epidemiological-cut-off (ECOFF) value, respectively. Non linear-mixed effects modelled the MTBC killing rates measured by Tuberculosis molecular bacterial load assay and culture. The median MIC at their 25th and 75th interquartile range (IQR) were compared using Mann-Whitney U test. Among 126 patients, 89 (71%) had positive culture whereas 87 (98%) were identified as M. tuberculosis. Overall, mutant (gNWT-R) MTBC isolates correlated with MIC values above the ECOFF. For instance, the median MIC (µg/mL) for rifampicin-gNWT-R strains was > 4.0 (IQR; 4.0 – 4.0) compared to 0.5 (IQR; 0.38 – 0.50) in non-mutant (gWT-S, p < 0.001); isoniazid-gNWT-R > 4.0 (IQR; 2.0 – 4.0) compared to 0.25 (IQR; 0.12 – 1.00) among gWT-S (p = 0.001); ethionamide-gNWT-R 15.0 (IQR; 10.0 – 20.0) compared to 2.50 (IQR; 2.50 – 5.00) among gWT-S (p < 0.001). There were no detectable mutations in genes previously known to confer fluoroquinolones, aminoglycosides, capreomycin, bedaquiline, delamanid, linezolid, clofazimine, cycloserine, and p aminosalicylic acid resistance. Compared to the adjusted M. tuberculosis killing rate of -0.17 (95% CI; -0.23 to -0.12) for the injectable without bedaquiline reference regimen, the killing rates were -0.62 (95% CI; -1.05 to -0.20) log10 eCFU/mL for the injectable with bedaquiline containing regimen (p = 0.019), -0.35 (95% CI; -0.65 to -0.13) log10 eCFU/mL for the all-oral bedaquiline-based regimen (p = 0.054), and -0.29 (95% CI; -0.78 to +0.22) log10 eCFU/mL for RHZE (p = 0.332). The detected M. tuberculosis was susceptible to core drugs including bedaquiline, fluoroquinolones, linezolid, and clofazimine, supporting their central use in the RR/MDRTB treatment regimens. M. tuberculosis killing rates were higher among patients who received bedaquiline but were further improved with addition of an injectable aminoglycoside.

show abstract

Section: Phenotypic Methodsmentioning

confidence: 99%

Application of molecular methods in optimizing clinical management of patients with pulmonary multidrug resistant tuberculosis in Tanzania

Mbelele

View full text Add to dashboard Cite

show abstract

Diagnostic accuracy of gold nanoparticle combined with molecular method for detection of Mycobacterium tuberculosis: A systematic review and meta-analysis study

Kadivarian¹,

Rostamian²,

Kooti³

et al. 2023

Sensing and Bio-Sensing Research

View full text Add to dashboard Cite

Rapid molecular diagnosis of live Mycobacterium tuberculosis on an integrated microfluidic system

Wang

Chang

Hung

et al. 2022

Sensors and Actuators B: Chemical

View full text Add to dashboard Cite

Microscopic detection of Mycobacterium tuberculosis in direct or processed sputum smears

Abstract: Increased sensitivity from analyzing PSS and better safety protocols will contribute to improved detection and control of the disease.

Cited by 6 publications

References 6 publications

Application of molecular methods in optimizing clinical management of patients with pulmonary multidrug resistant tuberculosis in Tanzania

Application of molecular methods in optimizing clinical management of patients with pulmonary multidrug resistant tuberculosis in Tanzania

Diagnostic accuracy of gold nanoparticle combined with molecular method for detection of Mycobacterium tuberculosis: A systematic review and meta-analysis study

Rapid molecular diagnosis of live Mycobacterium tuberculosis on an integrated microfluidic system

Contact Info

Product

Resources

About